Learn more about the transformation of psychedelics into medicines
Media
Press Releases
Title
Date
Eleusis Accelerates Psychedelic Drug Discovery and Development Team with Appointment of David Nichols, Ph.D., as Director of Molecular Pharmacology
Eleusis Accelerates Psychedelic Drug Discovery and Development Team with Appointment of David Nichols, Ph.D., as Director of Molecular Pharmacology
Jan. 11, 2021
Eleusis Launches Clinical Development of Psychedelic Infusion Therapies for Major Depressive Disorder and Acquires Kalypso Wellness Centers
Eleusis Launches Clinical Development of Psychedelic Infusion Therapies for Major Depressive Disorder and Acquires Kalypso Wellness Centers
Dec. 14, 2020
Eleusis Announces Published Preclinical Research Revealing Long Lasting Antidepressant-Like Effects of Psychedelics When Compared to Ketamine in Animals
Eleusis Announces Published Preclinical Research Revealing Long Lasting Antidepressant-Like Effects of Psychedelics When Compared to Ketamine in Animals
Mar. 5, 2020
Eleusis Announces Phase 1 Trial Results of Lysergic Acid Diethylamide (LSD) in Healthy Older Volunteers, Potential to Evaluate as Disease Modifying Therapy for Alzheimer’s Disease
Eleusis Announces Phase 1 Trial Results of Lysergic Acid Diethylamide (LSD) in Healthy Older Volunteers, Potential to Evaluate as Disease Modifying Therapy for Alzheimer’s Disease
Dec. 18, 2019
Eleusis Presents New Research on the Anti-Inflammatory Potential of Serotonin 2A Receptor Agonists at the 2019 International Society for Research on Psychedelics
Eleusis Presents New Research on the Anti-Inflammatory Potential of Serotonin 2A Receptor Agonists at the 2019 International Society for Research on Psychedelics
Oct. 23, 2019